Agenus (NASDAQ:AGEN) Stock Keeps Buy Rating at Chardan Capital

Agenus (NASDAQ:AGEN - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Chardan Capital in a research report issued to clients and investors on Thursday, Benzinga reports.

Other analysts have also issued research reports about the stock. B. Riley Financial reissued a "buy" rating and issued a $14.00 price target (up from $8.00) on shares of Agenus in a research report on Thursday, July 30th. Weiss Ratings raised shares of Agenus from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, October 8th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Wall Street Zen lowered shares of Agenus from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 17th. Finally, Rodman & Renshaw began coverage on shares of Agenus in a report on Monday, September 28th. They issued a "buy" rating and a $19.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $24.50.

Agenus Stock Down 0.3%

NASDAQ AGEN opened at $6.40 on Thursday. The company's 50 day moving average is $7.71 and its 200-day moving average is $5.48. Agenus has a 12-month low of $2.71 and a 12-month high of $10.31. The firm has a market cap of $289.04 million, a P/E ratio of 2.48 and a beta of 1.31.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. The business had revenue of $34.52 million during the quarter, compared to the consensus estimate of $34.00 million. Equities analysts expect that Agenus will post -0.30 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AGEN. Globeflex Capital L P bought a new position in shares of Agenus in the 2nd quarter worth $1,281,000. Bank of America Corp DE increased its holdings in shares of Agenus by 796.7% in the 1st quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company's stock worth $397,000 after buying an additional 105,536 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Agenus in the 2nd quarter worth $311,000. Finally, Everhart Financial Group Inc. bought a new position in shares of Agenus in the 3rd quarter worth $100,000. Institutional investors own 61.46% of the company's stock.

About Agenus

Agenus Inc NASDAQ: AGEN is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research programs are designed to activate and strengthen the immune system's ability to recognize and attack tumors, with an emphasis on therapies that may be used alone or in combination.

Agenus' pipeline includes botensilimab, an investigational Fc-enhanced CTLA-4 antibody, and balstilimab, an investigational PD-1 inhibitor. The company has studied these therapies in combination across several solid-tumor indications, including colorectal cancer and other advanced cancers.